RGLS Share Price

Open 0.87 Change Price %
High 0.87 1 Day -0.04 -4.60
Low 0.82 1 Week -0.09 -9.78
Close 0.83 1 Month -0.13 -13.54
Volume 751724 1 Year -2.60 -75.80
52 Week High 3.65
52 Week Low 0.82
RGLS Important Levels
Resistance 2 0.88
Resistance 1 0.86
Pivot 0.84
Support 1 0.80
Support 2 0.78
NASDAQ USA Most Active Stocks
DCTH 0.15 -11.76%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
QQQ 141.23 -0.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
FALC 0.25 38.89%
VRTA 4.50 38.46%
ESMC 0.13 30.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
STXS 0.68 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Regulus Therapeutics Inc. (NASDAQ: RGLS)

RGLS Technical Analysis 5
As on 18th Aug 2017 RGLS Share Price closed @ 0.83 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.83 & Strong Sell for SHORT-TERM with Stoploss of 1.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
RGLS Target for August
1st Target up-side 1.28
2nd Target up-side 1.44
3rd Target up-side 1.6
1st Target down-side 0.82
2nd Target down-side 0.66
3rd Target down-side 0.5
RGLS Other Details
Segment EQ
Market Capital 170651968.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
RGLS Address
RGLS
N/A
Interactive Technical Analysis Chart Regulus Therapeutics Inc. ( RGLS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regulus Therapeutics Inc.
RGLS Business Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012 , the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. The Company is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases.